The expression of estrogen, progesterone, and HER2 receptors in breast cancer cells helps guide treatment and predict outcomes. When the status of these receptors is heterogeneous, it makes treatment planning more complex. We present the case of a 72-year-old woman with bilateral breast cancer with heterogenous receptor status and subsequent challenges in management.
Keywords: breast cancer; heterogeneous hormone receptor status; synchronous bilateral breast cancer.
Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2024.